Section Arrow
Quote
PVLA.NASDAQ
- Palvella Therapeutics Inc
Quotes are at least 15-min delayed:2026/05/20 22:14 EDT
Regular Hours
Last
 115.5
+6.3 (+5.77%)
Day High 
115.5 
Prev. Close
109.2 
1-M High
138.64 
Volume 
220.97K 
Bid
114.84
Ask
175
Day Low
109.1 
Open
110.99 
1-M Low
101.29 
Market Cap 
1.57B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 118.06 
20-SMA 122.56 
50-SMA 123.27 
52-W High 151.18 
52-W Low 20.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-4.17/-6.32
Enterprise Value
1.57B
Balance Sheet
Book Value Per Share
16.20
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SLXNSilexion Therapeutics Corp0.5298+0.2608+96.95%-- 
JUNSJupiter Neurosciences Inc0.205-0.115-35.94%-- 
PHGEBiomX Inc.0.5969+0.2229+59.60%-- 
HCWBHCW Biologics Inc2.43+1.37+129.25%-- 
MTVAMetaVia Inc.2.89+1.01+53.72%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.